Overview

• The government published the names of 34 vendors with measured non-deliveries and gave them until the end of September to comply or face inhabilitation and contractual fines.
• Officials report overall supply near full—IMSS and ISSSTE about 97% and IMSS‑Bienestar lower—with remaining gaps linked to suppliers’ failures, including oncology lines from firms such as PiSA, Novag Infancia, Zurich Pharma and Amarox.
• Sheinbaum acknowledged outstanding invoices from 2024 and said they are being processed for payment, reiterating that winning bidders must meet delivery schedules.
• Industry associations pushed back, denying bad faith and citing delayed or irregular government payments, tight tender timelines and logistics constraints; unpaid estimates range from roughly 14,000 to 40,000 million pesos.
• For upcoming tenders, the administration plans to favor companies with plants in Mexico under Plan México to reduce reliance on imports, noting around 80% of bases for common drugs come from India and China.